Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
← catalyst calendarNCT05172726 · readout ≤ 73 d
Sponsored by Organon and Co (industry) · OGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
58actual
Sites
19
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-02 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Intervention
- Drug: tapinarof cream, 1%
Primary outcomes
what the primary-completion date above is the date OFAdverse Events (AEs) and Serious Adverse Events (SAEs)
measured Screening up to Week 53
Number of subjects with clinically significant laboratory test abnormalities
measured Screening up to Week 53
Number of subjects with clinically significant vital signs abnormalities
measured Screening up to Week 53
Investigator-Assessed Local Tolerability Scale (LTS) Scores
measured Baseline up to Week 52
Subject (or Caregiver)-Assessed Local Tolerability Scale (LTS)
measured Baseline up to Week 52
Publications
- PMID 38777187 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · OGN's whole pipeline · Catalyst calendar · Every registered study · What changed